Search
Lerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigationalLerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9). … [L54738] PCSK9 is a protein that binds to and promotes the degradation of low-density lipoprotein receptors (LDLRs), which are expressed on hepatocytes regulates circulating LDL levels.
Idursulfase
go.drugbank.com/drugs/DB01271ApprovedInvestigationalIdursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. … Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons.
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approved[L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573] … Technetium Tc-99m (<sup>99m</sup>Tc) succimer, also known as technetium Tc-99m dimercaptosuccinic acid (DMSA),[A245643] is a radioactive diagnostic agent used to evaluate functional renal tissue and tubular
Categories: Compounds used in a research, industrial, or household settingSpironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigationalSpironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. … [A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Mixtures: SPIRO D TABLINEN 100MG, Spirono Genericon comp. TablettenProducts: ALDACTONE A, SPIRONOLACTON 1A PHA 50MGTiclopidine
go.drugbank.com/drugs/DB00208ApprovedThe FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they … It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.
Products: TICLOPIDINA DOC GENERICI, TICLOPIDINA MYLAN GENERICSIndigotindisulfonic acid
go.drugbank.com/drugs/DB11577ApprovedInvestigationalIndigotindisulfonic acid is a blue-colored dye with a variety of uses. … [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to aid in visualizing ureter integrity in cystoscopic assessments.[L42600]
Categories: Compounds used in a research, industrial, or household settingBelinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalIntravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. … Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure.
Categories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexVimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalin a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results
CA-170
go.drugbank.com/drugs/DB15772InvestigationalCA-170 is a selective, small molecule inhibitor of PD-L1.
24-Homo-1,25-dihydroxyvitamin D3
go.drugbank.com/drugs/DB15557Experimental24-Homo-1,25-dihydroxyvitamin D3 is a novel [vitamin D] analogue.
Categories: Vitamin D and AnaloguesSynonyms: 24-Homo-1,25-dihydroxyvitamin D3